| 摘要 |
The present invention relates to soluble recombinant mutant human receptor activator of the NF-kB (RANK) protein which blocks interaction between human receptor activator of NF-kB ligand (RANKL) and wild type human RANK, and to a bone disease treatment composition using same. In detail, the present invention relates to soluble recombinant mutant human RANK protein and to a bone disease treatment composition using same, wherein the mutant human RANK protein encodes mutant RANK protein in which a leader peptide is connected to an N'-terminal end of the RANKL binding site of RANK protein, a human immunoglobulin G1 constant region (human Ig G1 Fc region) is connected to a C'-terminal end of the RANKL binding site of RANK protein, and glutamic acid of SEQ ID No: 97 amino acid of the RANKL binding site of the RANK protein is substituted (E97D) by aspartic acid. According to the present invention, using the soluble recombinant mutant human RANK, the interaction between soluble recombinant mutant human RANK and human RANKL is increased two times the E97D substitution and increased four times by E97D + C99F substitution. Accordingly, the soluble recombinant mutant human RANK can be effectively used as a therapeutic agent for bone diseases caused by bone metabolism disorders such as bone resorption inhibition, bone formation promotion, osteoporosis, osteoarthritis, multiple myeloma, hypercalcemia enhancement of the effects of soluble recombinant human rank using point mutations, and bone disease treatment composition using sameenhancement of the effects of soluble recombinant human rank using point mutations, and bone disease treatment composition using same.enhancement of the effects of soluble recombinant human rank using point mutations, and bone disease treatment composition using sameenhancement of the effects of soluble recombinant human rank using point mutations, and bone disease treatment composition using same.enhancement of the effects of soluble recombinant human rank using point mutations, and bone disease treatment composition using same |
